

For Health Professionals Who Care for People with Cancer

Inside This Issue

Editor's Choice

New Programs

GUAVEV: Palliative Therapy for Urothelial Carcinoma using Enfortumab Vedotin

Highlights of Revised Protocols and PPPOs

GUBEP, GUEP, GUVIP2: Etoposide Phosphate

SCDRUGRX: Management of Infusion-Related Reactions to Systemic Therapy Agents

Community Oncology Network

OSCAR Billing Deadline

Provincial Systemic Therapy Policies

Procedure III-110: Community Oncology Network Referral

Cancer Drug Manual®

New Enfortumab Vedotin Etoposide Phosphate **Revised** Decitabine-cedazuridine, Enfortumab vedotin, Etoposide, Etoposide Phosphate Leucovorin, Oxaliplatin, Chemotherapy Preparation and Stablitly Chart, IV Bag Size Selection Table

BC Cancer Benefit Drug List

New GUAVEV | Etoposide Phosphate (GUBEP, GUEP, GUVIP2)

New Protocols, PPPOs and Patient Handouts

GU GUAVEV

Revised Protocols, PPPOs and Patient Handouts

BR BRAJLHRHT, BRPCWTAC | **GI** GIAAVCT, UGIPRRT | **GU** GUAVPEM, GUAVPEM6, GUBEP, GUEP, GUSCARB, GUSCPE, GUSCPERT, GUTIP, GUVIP2 | **GO** UGOOVFNIRM, UGOOVNIRAM | **LU** LUAJOSI | **LY** LYGDP, LYGDPR, LYHDMRTEM, LYRICE, LYVENETOR | **LK** LKGEMOZ **MY** | MYBORPRE, MYBORREL, UMYCARDEX | **SA** SAAVIME3, SAIME | **SC** SCMESNA for SAIME SAAVIME3, SCORRX

Resources and Contact Information

Editor's Choice

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment program effective 1 March 2023. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

Genitourinary

Palliative Therapy for Urothelial Carcinoma using Enfortumab Vedotin (GUAVEV) — The BC Cancer Genitourinary Tumour Group is introducing enfortumab vedotin for the treatment of patients with unresectable, locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and PD-1 or PD-L1 inhibitor therapy. There are currently no standard treatment at BC Cancer for third-line treatment of urothelial cancer.

Enfortumab vedotin is a monoclonal antibody conjugated with a cytotoxic antimicrotubule agent. The use of enfortumab vedotin in this patient population is supported by supported by the randomized, open-label, active-controlled phase III EV-301 study. Compared to salvage chemotherapy, enfortumab vedotin

Editor's Choice

was associated with increased overall survival (12.88 mos vs. 8.97 mos, hazard ratio [HR] 0.702) and progression-free survival (5.55 mos vs. 3.71 mos, HR 0.615), and overall response rate (40.6% vs. 17.9%). Enfortumab vedotin was associated with a high but manageable overall incidence of toxicities. Grade 3 or higher toxicities occurred in 51.4% of patients, including maculopapular rash (7.4%), fatigue (6.4%), and decreased neutrophil count (6.1%).¹

References

1. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. *N Engl J Med* 2021;384(12):1125-35.

Highlights of Revised Protocols and PPPOs

Genitourinary

Etoposide phosphate option – The BC Cancer Genitourinary Tumour Group is adding etoposide phosphate option as alternative for GUBEP, GUEP and GUVIP2 protocols and PPPOs for patients with severe hypersensitivity to etoposide. Etoposide phosphate is not commercially available in Canada and must be obtained via Health Canada Special Access Program (SAP).

Note that since these protocols are given with curative intent, it is important to complete the treatment course over 5 consecutive days as specified. The decision to offer treatment over less than 5 days should be reserved for exceptional situations and consider discussion with the most responsible physician (MRP) before deviation from the standard 5-day treatment.

Supportive Care

SCDRUGRX Protocol (Management of Infusion-Related Reactions to Systemic Therapy Agents) – The SCDRUGRX protocol will be updated and posted on 3 April 2023. Highlights of the updates include:

- SCDRUGRX protocol revisions focused around *Subsequent Management After An Infusion-Related Reaction*
- Minor revisions to *PPO-A: Immediate management of infusion-related reaction and resumption of infusion*
- Launch of the provincial *PPO-B: Subsequent cycle infusion administration after infusion-related reaction*

Please watch this space for updates in the next issue of Systemic Therapy Update.

Community Oncology Network (CON)

2022-2023 OSCAR Billing Deadline: 05 April 2023

The 2022-2023 fiscal year will end on Friday 31 March 2023. To meet the deadline for external reporting to the Ministry of Health, all claims for drug reimbursement for the current fiscal year must be submitted by **Wednesday 05 April 2023** via **OSCAR** (Online System for Cancer Drugs Adjudication and Reimbursement). Any claims submitted after this date will not be eligible for reimbursement. For more information, please e-mail oscar@bccancer.bc.ca.

Provincial Systemic Therapy Policies

Procedure III-110: Community Oncology Network Referral

This policy has been updated with the followings:

- Documentation clarification for Health Information Management (HIM) clerks
- Name Change for clarification
- Transition from Policy to Procedure due to content

Cancer Drug Manual[©]

All documents are available in the [Cancer Drug Manual[©]](#) on the BC Cancer website.

New Documents

The **Enfortumab vedotin Interim Monograph** has been expanded into a full **Monograph** and a **Patient Handout** has been developed. Expert review was provided by Dr. Jean-Michel Lavoie (medical oncologist, BC Cancer Genitourinary Tumour Group) and Megan Darbyshire (tumour group pharmacist, BC Cancer Provincial Pharmacy). All monograph sections have been reviewed and updated. The following sections have been added or expanded: *Pharmacokinetics, Special Precautions, Side Effects, Interactions, and Dosage Guidelines*. **Enfortumab vedotin** is a Nectin-4 directed antibody-drug conjugate used in the treatment of urothelial carcinoma. The usual dose is 1.25 mg/kg IV every four weeks.

Highlights from these document include:

- hyperglycemia and diabetic ketoacidosis have been reported in patients without pre-existing diabetes mellitus and was sometimes fatal
- extravasation may cause skin and soft tissue reactions; symptom onset may be delayed and symptoms may initially worsen before resolving
- ocular disorders are common and may require topical corticosteroids; artificial tears may be used as prophylaxis for dry eyes

The **Etoposide phosphate Patient Handout** has been developed. Etoposide phosphate has been suggested as an alternative to etoposide in cases of severe hypersensitivity reaction to etoposide. Etoposide phosphate is not commercially available in Canada and must be obtained via Health Canada Special Access Program (SAP).

Revised Documents

Decitabine-cedazuridine Monograph

Supply and Storage: clarified blister packaging information

Enfortumab vedotin Chemotherapy Preparation and Stability Chart

New brand: added marketed supply (Seagen). Note that in-line filter is not required according to the Canadian manufacturer.

SAP supply: deleted SAP supply (Astellas)

Etoposide IV Patient Handout

Throughout: updated to current CDM template wording

Etoposide Oral Patient Handout

Throughout: updated to current CDM template wording

Bullets: added information about twice daily dosing

Etoposide Phosphate Monograph

Special Precautions: added information regarding substitution for etoposide for hypersensitivity reactions

Supply and Storage: updated to include information about the Health Canada Special Access Program

Parenteral Administration table: updated suggested administration time

Leucovorin Monograph

Supply and Storage: added excipient information (trometamol) to GMP brand leucovorin

Oxaliplatin Monograph

Solution Preparation and Compatibility: clarified information pertaining to administration of oxaliplatin with leucovorin

Chemotherapy Preparation and Stability Chart

Carboplatin (*Product column*): updated volume range for recommended bag volume

Gemtuzumab ozogamicin (*Product column*): updated volume range for recommended bag volume

IV Bag Size Selection Table

Solution Preparation and Compatibility: clarified information pertaining to administration of oxaliplatin with leucovorin

BC Cancer Benefit Drug List

New Programs

The following treatment program has been added to the [Benefit Drug List](#) effective 01 March 2023:

Protocol Title	Protocol Code	Benefit Status
Palliative Therapy for Urothelial Carcinoma using Enfortumab Vedotin	GUAVEV	Class I

Revised Programs

Etoposide phosphate has been added to the [Benefit Drug List](#) for the following programs effective 01 March 2023:

Protocol Title	Protocol Code	Benefit Status
Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide and CISplatin	GUBEP	Class I
Etoposide-CISplatin Protocol for Germ Cell Cancers	GUEP	Class I
Consolidation and Salvage Therapy for Nonseminoma Using Etoposide, CISplatin, Ifosfamide, Mesna	GUVIP2	Class I

New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GUAVEV	Palliative Therapy for Urothelial Carcinoma using Enfortumab Vedotin	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Revised Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
BRAJLHRHT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using a LHRH Agonist and Tamoxifen	<i>treatment duration revised</i>	--	--
BRPCWTAC	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide	<i>bag size clarified</i>	<i>bag size clarified</i>	--
GI Gastrointestinal				
GIAAVCT	First-Line Palliative Treatment of Metastatic Anal Squamous Cell Carcinoma Using CARBOplatin and Weekly PACLitaxel	--	<i>tests clarified</i>	--
UGIPRRT	Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium ¹⁷⁷ Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours	<i>eligibility updated, tests removed</i>	<i>tests removed</i>	--
GU Genitourinary				
GUAVPEM	Treatment of Locally Advanced or Metastatic Urothelial Carcinoma Using Pembrolizumab	<i>exclusions updated</i>	--	--
GUAVPEM6	Treatment of Locally Advanced or Metastatic Urothelial Carcinoma Using 6-Weekly Pembrolizumab	<i>exclusions updated</i>	--	--
GUBEP	Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide and CISplatin	<i>etoposide phosphate added, etoposide bag size clarified, premedications, precautions and referencs updated</i>	<i>etoposide phosphate added, premedications updated</i>	<i>treatment summary, medication interactions, during or after treatment, side effects table and instructions for the patient updated</i>
GUEP	Etoposide-CISplatin Protocol for Germ Cell Cancers	<i>etoposide phosphate added, premedications, precautions and references updated</i>	<i>etoposide phosphate added, premedications updated</i>	<i>treatment summary, medication interactions, during or after treatment, side effects table and instructions for the patient updated</i>

Revised Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GUSCARB	Adjuvant Therapy for Stage I High Risk Seminoma Using CARBOplatin	<i>premedications updated</i>	<i>premedications updated</i>	--
GUSCPE	Palliative Therapy of Extensive Stage Genitourinary Small Cell Tumours with a Platinum and Etoposide	<i>premedications updated, cisplatin bag size clarified</i>	<i>premedications updated</i>	--
GUSCPERT	Therapy of Genitourinary Small Cell Tumors with a Platin and Etoposide with Radiation	<i>premedications updated, cisplatin bag size clarified</i>	<i>premedications updated</i>	--
GUTIP	Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)	--	<i>VCC Inpatient PPO: ranitidine replaced with famotidine</i>	--
GUVIP2	Consolidation and Salvage Therapy for Nonseminoma Using Etoposide, CISplatin, Ifosfamide, Mesna	<i>Etoposide phosphate added, premedications, dose modifications, precautions and references updated</i>	<i>VCC Inpatient PPO: etoposide phosphate added</i>	<i>treatment summary, medication interactions, during or after treatment, side effects table and instructions for the patient updated</i>
GO Gynecologic				
UGOOVFNIRM	Maintenance Treatment of Newly Diagnosed Platinum Responsive Epithelial Ovarian Cancer using Niraparib	<i>eligibility revised, typo corrected</i>	--	--
UGOOVNIRAM	Maintenance Treatment of Relapsed Platinum Sensitive and Responsive Epithelial Ovarian Cancer using Niraparib	<i>eligibility revised</i>	--	--
LK Leukemia				
LKGEMOZ	Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin with Induction and Consolidation	<i>premedications revised, dose rounding removed, gemtuzumab ozogamicin bag size updated</i>	--	--
LU Lung				
LUAJOSI	Adjuvant Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) with Osimertinib	<i>drug name clarified</i>	--	--
LY Lymphoma				
LYGDP	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Platinum	<i>premedications updated, auxiliary information removed</i>	<i>premedications updated</i>	--

Revised Protocols, PPOs and Patient Handouts (revisions in respective columns)

Protocol Code	Protocol Title	Protocol	PPO	Handout
LYGDPR	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Platinum with riTUXimab	<i>premedications updated, auxiliary information removed</i>	<i>premedications updated</i>	--
LYHDMRTEM	Treatment of Primary and Secondary CNS Lymphoma with High Dose Methotrexate, riTUXimab and temozolomide	<i>supportive medications updated</i>	<i>supportive medications updated</i>	--
LYRICE	Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin's Lymphoma with Ifosfamide, CARBOplatin, Etoposide and riTUXimab	<i>premedications updated, CARBOplatin dosing clarified</i>	<i>premedications updated, CARBOplatin dosing clarified</i>	--
LYVENETOR	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Venetoclax and riTUXimab	<i>eligibility and exclusions clarified and updated</i>	--	--
MY Myeloma				
MYBORPRE	Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant	-	<i>treatment clarified</i>	--
MYBORREL	Treatment of Relapsed Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide	-	<i>treatment clarified</i>	--
UMYCARDEX	Therapy of Multiple Myeloma Using Carfilzomib and Dexamethasone With or Without Cyclophosphamide	-	<i>treatment clarified</i>	--
SA Sarcoma				
SAAVIME3	3-Day Etoposide and Ifosfamide-Mesna for Patients with Advanced Soft Tissue or Bony Sarcomas	<i>premedications updated</i>	<i>VCC Inpatient PPO: ranitidine replaced with famotidine</i>	--
SAIME	Etoposide, Ifosfamide-Mesna (SAIME) for Use in Sarcomas	--	<i>VCC Inpatient PPO: ranitidine replaced with famotidine, electrolytes clarified</i>	--
SC Supportive Care				
SCMESNA for SAIME SAAVIME3	MESNA Dosage Modification for Hematuria Secondary to Oxazaphosphorines (e.g. Ifosfamide and Cyclophosphamide)	--	<i>VCC Inpatient PPO: ranitidine replaced with famotidine</i>	--
SCOXRX	Oxaliplatin Desensitization	<i>premedications updated</i>	--	--

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
CST Bulletin: http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/cst-bulletin		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
Nurse Educators	604-877-6000 x 672638	nursinged@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Manufacturer Patient Assistance Programs: http://www.bccancer.bc.ca/mpap		
Library/Cancer Information	604-675-8003	requests@bccancer.bc.ca toll free 888-675-8001 x 8003
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247	mclin@bccancer.bc.ca
Professional Practice, Nursing	604-877-6000 x 672623	BCcancerPPNAdmin@ehcnet.phsa.ca
Provincial Systemic Therapy	604-877-6000 x 672247	mclin@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)
 Fatima Ladha, BScPharm, PharmD (Assistant Editor)
 Mario de Lemos, PharmD, MSc(Oncol)
 Jeevan Dosanjh, RN, BScN

Alina Gerrie, MD, MPH, FRCPC
 Samuel Hackett, RN, BScN, CON(C)
 Alison Pow, BScPharm